Daliresp is a selective PDE4 inhibitor, indicated as a treatment for reducing the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Forest Labs has received the US Food and Drug Adminstration’s (FDA) approval for Daliresp on 1 March 2011.
The drug has showed efficacy and safety profile when evaluated in eight clinical studies involving 9,394 adult patients.
Earlier, Forest Labs has got license for Daliresp in the US, under an agreement signed with Nycomed.